Standard-dose tegafur-uracil (UFT) is not a safe alternative in partial dihydropyrimidine dehydrogenase-deficient patients
- PMID: 23323150
- PMCID: PMC3539277
- DOI: 10.1177/1758834012464806
Standard-dose tegafur-uracil (UFT) is not a safe alternative in partial dihydropyrimidine dehydrogenase-deficient patients
Conflict of interest statement
References
-
- Deenen M., Cats A., Sechterberger M., Severens J., Smits P., Bakker R., et al. (2011) Safety, pharmacokinetics (PK), and cost-effectiveness of upfront genotyping of DPYD in fluoropyrimidine therapy. J Clin Oncol 29(Suppl. 15): 3606
-
- Deenen M., Terpstra W., Cats A., Boot H., Schellens J. (2010) Standard-dose tegafur combined with uracil is not safe treatment after severe toxicity from 5-fluorouracil or capecitabine. Ann Intern Med 153: 767–768 - PubMed
-
- Ho D., Pazdur R., Covington W., Brown N., Huo Y., Lassere Y., et al. (1998) Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2’-tetrahydrofuryl)-5-fluorouracil. Clin Cancer Res 4: 2085–2088 - PubMed
LinkOut - more resources
Full Text Sources
